Fabio Baccetti
Research Subjects
Fabio Baccetti has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Ozzello
AMD Regional Past President, AI AMD National Group, 10090 Bruino, Italy
1 shared publication Andrea Michelli
Department of Internal Medicine, SC Diabetes and Center for Treatment of Diabetic Foot, Monfalcone, Gorizia, Italy
1 shared publication- Antonio Nicolucci
Center for Outcomes Research and Clinical Epidemiology (CORESEARCH), Pescara, Italy
1 shared publication - Antonio Rossi
IRCCS Ospedale Galeazzi-Sant’Ambrogio, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
1 shared publication - Besmir Nreu
Diabetology Unit, Careggi Hospital, Largo G.A. Brambilla, 3, 50134 Florence (FI), Italy
1 shared publication - Carlo Bruno Giorda
Metabolism and Diabetes Unit, ASL TO5, Regione Piemonte, Chieri, Italy
1 shared publication
Latest Publications
- Open Access
- 11 July 2024
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 214, 111781
Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years
- 11 July 2024
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 214, 111781
Open AccessProfiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years
- Open Access
- 14 February 2024
- Published by MDPI AG in Machine Learning and Knowledge Extraction
- Vol. 6 (1) , 420-434
Overcoming Therapeutic Inertia in Type 2 Diabetes: Exploring Machine Learning-Based Scenario Simulation for Improving Short-Term Glycemic Control
Background: International guidelines for diabetes care emphasize the urgency of promptly achieving and sustaining adequate glycemic control to reduce the occurrence of micro/macrovascular complications in patients with type 2 diabetes mellitus (T2DM). However, data from the Italian Association of Medical Diabetologists (AMD) Annals reveal that only 47% of T2DM patients reach appropriate glycemic targets, with approximately 30% relying on insulin therapy, either solely or in combination. This artificial intelligence analysis seeks to assess the potential impact of timely insulin initiation in all eligible patients via a “what-if” scenario simulation, leveraging real-world data. Methods: This retrospective cohort study utilized the AMD Annals database, comprising 1,186,247 T2DM patients from 2005 to 2019. Employing the Logic Learning Machine (LLM), we simulated timely insulin use for all eligible patients, estimating its effect on glycemic control after 12 months within a cohort of 85,239 patients. Of these, 20,015 were employed for the machine learning phase and 65,224 for simulation. Results: Within the simulated scenario, the introduction of appropriate insulin therapy led to a noteworthy projected 17% increase in patients meeting the metabolic target after 12 months from therapy initiation within the cohort of 65,224 individuals. The LLM’s projection envisages 32,851 potential patients achieving the target (hemoglobin glycated < 7.5%) after 12 months, compared to 21,453 patients observed in real-world cases. The receiver operating characteristic (ROC) curve analysis for this model demonstrated modest performance, with an area under the curve (AUC) value of 70.4%. Conclusions: This study reaffirms the significance of combatting therapeutic inertia in managing T2DM patients. Early insulinization, when clinically appropriate, markedly enhances patients’ metabolic goals at the 12-month follow-up.
- 14 February 2024
- Published by MDPI AG in Machine Learning and Knowledge Extraction
- Vol. 6 (1) , 420-434
Open AccessOvercoming Therapeutic Inertia in Type 2 Diabetes: Exploring Machine Learning-Based Scenario Simulation for Improving Short-Term Glycemic Control
Background: International guidelines for diabetes care emphasize the urgency of promptly achieving and sustaining adequate glycemic control to reduce the occurrence of micro/macrovascular complications in patients with type 2 diabetes mellitus (T2DM). However, data from the Italian Association of Medical Diabetologists (AMD) Annals reveal that only 47% of T2DM patients reach appropriate glycemic targets, with approximately 30% relying on insulin therapy, either solely or in combination. This artificial intelligence analysis seeks to assess the potential impact of timely insulin initiation in all eligible patients via a “what-if” scenario simulation, leveraging real-world data. Methods: This retrospective cohort study utilized the AMD Annals database, comprising 1,186,247 T2DM patients from 2005 to 2019. Employing the Logic Learning Machine (LLM), we simulated timely insulin use for all eligible patients, estimating its effect on glycemic control after 12 months within a cohort of 85,239 patients. Of these, 20,015 were employed for the machine learning phase and 65,224 for simulation. Results: Within the simulated scenario, the introduction of appropriate insulin therapy led to a noteworthy projected 17% increase in patients meeting the metabolic target after 12 months from therapy initiation within the cohort of 65,224 individuals. The LLM’s projection envisages 32,851 potential patients achieving the target (hemoglobin glycated < 7.5%) after 12 months, compared to 21,453 patients observed in real-world cases. The receiver operating characteristic (ROC) curve analysis for this model demonstrated modest performance, with an area under the curve (AUC) value of 70.4%. Conclusions: This study reaffirms the significance of combatting therapeutic inertia in managing T2DM patients. Early insulinization, when clinically appropriate, markedly enhances patients’ metabolic goals at the 12-month follow-up.